Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
AgBiome has secured a new patent for its Connate product line, strengthening its intellectual property (IP) protection around innovative agricultural products. The Connate products will enhance the existing Howler fungicide by reducing chemical residues while maintaining efficacy. AgBiome holds 264 pending patent applications and 28 granted patents, asserting a robust position in the crop protection sector. The company continues to innovate through its GENESIS platform, discovering and developing microbial solutions to improve agricultural practices.
AgBiome has submitted its new fungicide, Theia™, to the EPA for review, marking its second biological fungicide launch in three years. Theia, developed through the GENESIS™ discovery platform, aims to address growing pest resistance and offers a unique mode of action compared to synthetic options. The company emphasizes its strong product pipeline and commitment to sustainable growth in agriculture. AgBiome also collaborates with Elanco Animal Health to develop nutritional health products, reinforcing its position in the crop protection market.